Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors
Identifieur interne : 003511 ( Main/Exploration ); précédent : 003510; suivant : 003512Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors
Auteurs : Arun K. Ghosh [États-Unis] ; GANGLI GONG [États-Unis] ; Valerie Grum-Tokars [États-Unis] ; Debbie C. Mulhearn [États-Unis] ; Susan C. Baker [États-Unis] ; Melissa Coughlin [États-Unis] ; Bellur S. Prabhakar [États-Unis] ; Katrina Sleeman [États-Unis] ; Michael E. Johnson [États-Unis] ; Andrew D. Mesecar [États-Unis]Source :
- Bioorganic & medicinal chemistry letters : (Print) [ 0960-894X ] ; 2008.
Descripteurs français
- KwdFr :
- Animaux, Antiviraux (), Antiviraux (pharmacologie), Antiviraux (synthèse chimique), Chimie pharmaceutique (), Concentration inhibitrice 50, Conception de médicament, Conformation moléculaire, Cysteine endopeptidases (), Domaine catalytique, Esters, Humains, Liaison aux protéines, Modèles chimiques, Modèles moléculaires, Protéines virales (antagonistes et inhibiteurs), Virus du SRAS (métabolisme).
- MESH :
- antagonistes et inhibiteurs : Protéines virales.
- métabolisme : Virus du SRAS.
- pharmacologie : Antiviraux.
- synthèse chimique : Antiviraux.
- Pascal (Inist)
- Animaux, Antiviraux, Chimie pharmaceutique, Concentration inhibitrice 50, Conception de médicament, Conformation moléculaire, Cysteine endopeptidases, Domaine catalytique, Esters, Humains, Liaison aux protéines, Modèles chimiques, Modèles moléculaires, Synthèse chimique, Antiviral, Relation structure activité, In vitro, Cysteine endopeptidases, Virus syndrome respiratoire aigu sévère, Hétérocycle azote, Composé bicyclique, Composé aromatique, Dérivé de la pyridine, Modèle moléculaire, Complexe enzyme inhibiteur, Modélisation, Inhibiteur enzyme, Indole-4-carboxylique acide ester 5-chloro-3-pyridyle.
English descriptors
- KwdEn :
- Animals, Antiviral, Antiviral Agents (chemical synthesis), Antiviral Agents (chemistry), Antiviral Agents (pharmacology), Aromatic compound, Bicyclic compound, Catalytic Domain, Chemical synthesis, Chemistry, Pharmaceutical (methods), Cysteine Endopeptidases (chemistry), Cysteine endopeptidases, Drug Design, Enzyme inhibitor, Esters, Humans, In vitro, Inhibitor enzyme complex, Inhibitory Concentration 50, Modeling, Models, Chemical, Models, Molecular, Molecular Conformation, Molecular model, Nitrogen heterocycle, Protein Binding, Pyridine derivatives, SARS Virus (metabolism), Severe acute respiratory syndrome virus, Structure activity relation, Viral Proteins (antagonists & inhibitors).
- MESH :
- chemical , antagonists & inhibitors : Viral Proteins.
- chemical , chemical synthesis : Antiviral Agents.
- chemical , chemistry : Antiviral Agents, Cysteine Endopeptidases.
- chemical , pharmacology : Antiviral Agents.
- metabolism : SARS Virus.
- methods : Chemistry, Pharmaceutical.
- Animals, Catalytic Domain, Drug Design, Esters, Humans, Inhibitory Concentration 50, Models, Chemical, Models, Molecular, Molecular Conformation, Protein Binding.
Abstract
Design, synthesis and biological evaluation of a series of 5-chloropyridine ester-derived severe acute respiratory syndrome-coronavirus chymotrypsin-like protease inhibitors is described. Position of the carboxylate functionality is critical to potency. Inhibitor 10 with a 5-chloropyridinyl ester at position 4 of the indole ring is the most potent inhibitor with a SARS-CoV 3CLpro IC50 value of 30 nM and an antiviral EC50 value of 6.9 μM. Molecular docking studies have provided possible binding modes of these inhibitors.
Url:
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000241
- to stream PascalFrancis, to step Curation: 000747
- to stream PascalFrancis, to step Checkpoint: 000291
- to stream Main, to step Merge: 003617
- to stream Pmc, to step Corpus: 000834
- to stream Pmc, to step Curation: 000834
- to stream Pmc, to step Checkpoint: 000E31
- to stream PubMed, to step Corpus: 001A67
- to stream PubMed, to step Curation: 001A67
- to stream PubMed, to step Checkpoint: 001B59
- to stream Ncbi, to step Merge: 001D48
- to stream Ncbi, to step Curation: 001D48
- to stream Ncbi, to step Checkpoint: 001D48
- to stream Main, to step Merge: 003225
- to stream Main, to step Curation: 003511
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors</title><author><name sortKey="Ghosh, Arun K" sort="Ghosh, Arun K" uniqKey="Ghosh A" first="Arun K." last="Ghosh">Arun K. Ghosh</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Departments of Chemistry and Medicinal Chemistry. Purdue University, 560 Oval drive</s1><s2>West Lafayette, IN 47907</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Gangli Gong" sort="Gangli Gong" uniqKey="Gangli Gong" last="Gangli Gong">GANGLI GONG</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Departments of Chemistry and Medicinal Chemistry. Purdue University, 560 Oval drive</s1><s2>West Lafayette, IN 47907</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Grum Tokars, Valerie" sort="Grum Tokars, Valerie" uniqKey="Grum Tokars V" first="Valerie" last="Grum-Tokars">Valerie Grum-Tokars</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Center for Pharmaceutical Biotechnology, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 900 S</s1><s2>Ashland, IL 60607</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region><settlement type="city">Chicago</settlement></placeName><orgName type="university">Université de l'Illinois à Chicago</orgName></affiliation></author><author><name sortKey="Mulhearn, Debbie C" sort="Mulhearn, Debbie C" uniqKey="Mulhearn D" first="Debbie C." last="Mulhearn">Debbie C. Mulhearn</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Center for Pharmaceutical Biotechnology, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 900 S</s1><s2>Ashland, IL 60607</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region><settlement type="city">Chicago</settlement></placeName><orgName type="university">Université de l'Illinois à Chicago</orgName></affiliation></author><author><name sortKey="Baker, Susan C" sort="Baker, Susan C" uniqKey="Baker S" first="Susan C." last="Baker">Susan C. Baker</name><affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Department of Microbiology and Immunology, Loyola University of Chicago, Stritch School of Medicine</s1><s2>Maywood, IL</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region><settlement type="city">Chicago</settlement></placeName><orgName type="university">Université de Chicago</orgName></affiliation></author><author><name sortKey="Coughlin, Melissa" sort="Coughlin, Melissa" uniqKey="Coughlin M" first="Melissa" last="Coughlin">Melissa Coughlin</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Microbiology and Immunology, University of Illinois</s1><s2>Chicago, IL 60607</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Prabhakar, Bellur S" sort="Prabhakar, Bellur S" uniqKey="Prabhakar B" first="Bellur S." last="Prabhakar">Bellur S. Prabhakar</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Microbiology and Immunology, University of Illinois</s1><s2>Chicago, IL 60607</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Sleeman, Katrina" sort="Sleeman, Katrina" uniqKey="Sleeman K" first="Katrina" last="Sleeman">Katrina Sleeman</name><affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Department of Microbiology and Immunology, Loyola University of Chicago, Stritch School of Medicine</s1><s2>Maywood, IL</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region><settlement type="city">Chicago</settlement></placeName><orgName type="university">Université de Chicago</orgName></affiliation></author><author><name sortKey="Johnson, Michael E" sort="Johnson, Michael E" uniqKey="Johnson M" first="Michael E." last="Johnson">Michael E. Johnson</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Center for Pharmaceutical Biotechnology, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 900 S</s1><s2>Ashland, IL 60607</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region><settlement type="city">Chicago</settlement></placeName><orgName type="university">Université de l'Illinois à Chicago</orgName></affiliation></author><author><name sortKey="Mesecar, Andrew D" sort="Mesecar, Andrew D" uniqKey="Mesecar A" first="Andrew D." last="Mesecar">Andrew D. Mesecar</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Center for Pharmaceutical Biotechnology, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 900 S</s1><s2>Ashland, IL 60607</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region><settlement type="city">Chicago</settlement></placeName><orgName type="university">Université de l'Illinois à Chicago</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">09-0033367</idno><date when="2008">2008</date><idno type="stanalyst">PASCAL 09-0033367 INIST</idno><idno type="RBID">Pascal:09-0033367</idno><idno type="wicri:Area/PascalFrancis/Corpus">000241</idno><idno type="wicri:Area/PascalFrancis/Curation">000747</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000291</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000291</idno><idno type="wicri:doubleKey">0960-894X:2008:Ghosh A:design:synthesis:and</idno><idno type="wicri:Area/Main/Merge">003617</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2745596</idno><idno type="RBID">PMC:2745596</idno><idno type="wicri:Area/Pmc/Corpus">000834</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000834</idno><idno type="wicri:Area/Pmc/Curation">000834</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000834</idno><idno type="wicri:Area/Pmc/Checkpoint">000E31</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000E31</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:18796354</idno><idno type="wicri:Area/PubMed/Corpus">001A67</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A67</idno><idno type="wicri:Area/PubMed/Curation">001A67</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A67</idno><idno type="wicri:Area/PubMed/Checkpoint">001B59</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001B59</idno><idno type="wicri:Area/Ncbi/Merge">001D48</idno><idno type="wicri:Area/Ncbi/Curation">001D48</idno><idno type="wicri:Area/Ncbi/Checkpoint">001D48</idno><idno type="wicri:doubleKey">0960-894X:2008:Ghosh A:design:synthesis:and</idno><idno type="wicri:Area/Main/Merge">003225</idno><idno type="wicri:Area/Main/Curation">003511</idno><idno type="wicri:Area/Main/Exploration">003511</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors</title><author><name sortKey="Ghosh, Arun K" sort="Ghosh, Arun K" uniqKey="Ghosh A" first="Arun K." last="Ghosh">Arun K. Ghosh</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Departments of Chemistry and Medicinal Chemistry. Purdue University, 560 Oval drive</s1><s2>West Lafayette, IN 47907</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Gangli Gong" sort="Gangli Gong" uniqKey="Gangli Gong" last="Gangli Gong">GANGLI GONG</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Departments of Chemistry and Medicinal Chemistry. Purdue University, 560 Oval drive</s1><s2>West Lafayette, IN 47907</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Grum Tokars, Valerie" sort="Grum Tokars, Valerie" uniqKey="Grum Tokars V" first="Valerie" last="Grum-Tokars">Valerie Grum-Tokars</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Center for Pharmaceutical Biotechnology, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 900 S</s1><s2>Ashland, IL 60607</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region><settlement type="city">Chicago</settlement></placeName><orgName type="university">Université de l'Illinois à Chicago</orgName></affiliation></author><author><name sortKey="Mulhearn, Debbie C" sort="Mulhearn, Debbie C" uniqKey="Mulhearn D" first="Debbie C." last="Mulhearn">Debbie C. Mulhearn</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Center for Pharmaceutical Biotechnology, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 900 S</s1><s2>Ashland, IL 60607</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region><settlement type="city">Chicago</settlement></placeName><orgName type="university">Université de l'Illinois à Chicago</orgName></affiliation></author><author><name sortKey="Baker, Susan C" sort="Baker, Susan C" uniqKey="Baker S" first="Susan C." last="Baker">Susan C. Baker</name><affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Department of Microbiology and Immunology, Loyola University of Chicago, Stritch School of Medicine</s1><s2>Maywood, IL</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region><settlement type="city">Chicago</settlement></placeName><orgName type="university">Université de Chicago</orgName></affiliation></author><author><name sortKey="Coughlin, Melissa" sort="Coughlin, Melissa" uniqKey="Coughlin M" first="Melissa" last="Coughlin">Melissa Coughlin</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Microbiology and Immunology, University of Illinois</s1><s2>Chicago, IL 60607</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Prabhakar, Bellur S" sort="Prabhakar, Bellur S" uniqKey="Prabhakar B" first="Bellur S." last="Prabhakar">Bellur S. Prabhakar</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Microbiology and Immunology, University of Illinois</s1><s2>Chicago, IL 60607</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Sleeman, Katrina" sort="Sleeman, Katrina" uniqKey="Sleeman K" first="Katrina" last="Sleeman">Katrina Sleeman</name><affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Department of Microbiology and Immunology, Loyola University of Chicago, Stritch School of Medicine</s1><s2>Maywood, IL</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region><settlement type="city">Chicago</settlement></placeName><orgName type="university">Université de Chicago</orgName></affiliation></author><author><name sortKey="Johnson, Michael E" sort="Johnson, Michael E" uniqKey="Johnson M" first="Michael E." last="Johnson">Michael E. Johnson</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Center for Pharmaceutical Biotechnology, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 900 S</s1><s2>Ashland, IL 60607</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region><settlement type="city">Chicago</settlement></placeName><orgName type="university">Université de l'Illinois à Chicago</orgName></affiliation></author><author><name sortKey="Mesecar, Andrew D" sort="Mesecar, Andrew D" uniqKey="Mesecar A" first="Andrew D." last="Mesecar">Andrew D. Mesecar</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Center for Pharmaceutical Biotechnology, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 900 S</s1><s2>Ashland, IL 60607</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region><settlement type="city">Chicago</settlement></placeName><orgName type="university">Université de l'Illinois à Chicago</orgName></affiliation></author></analytic><series><title level="j" type="main">Bioorganic & medicinal chemistry letters : (Print)</title><title level="j" type="abbreviated">Bioorg. med. chem. lett. : (Print)</title><idno type="ISSN">0960-894X</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Bioorganic & medicinal chemistry letters : (Print)</title><title level="j" type="abbreviated">Bioorg. med. chem. lett. : (Print)</title><idno type="ISSN">0960-894X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral</term><term>Antiviral Agents (chemical synthesis)</term><term>Antiviral Agents (chemistry)</term><term>Antiviral Agents (pharmacology)</term><term>Aromatic compound</term><term>Bicyclic compound</term><term>Catalytic Domain</term><term>Chemical synthesis</term><term>Chemistry, Pharmaceutical (methods)</term><term>Cysteine Endopeptidases (chemistry)</term><term>Cysteine endopeptidases</term><term>Drug Design</term><term>Enzyme inhibitor</term><term>Esters</term><term>Humans</term><term>In vitro</term><term>Inhibitor enzyme complex</term><term>Inhibitory Concentration 50</term><term>Modeling</term><term>Models, Chemical</term><term>Models, Molecular</term><term>Molecular Conformation</term><term>Molecular model</term><term>Nitrogen heterocycle</term><term>Protein Binding</term><term>Pyridine derivatives</term><term>SARS Virus (metabolism)</term><term>Severe acute respiratory syndrome virus</term><term>Structure activity relation</term><term>Viral Proteins (antagonists & inhibitors)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antiviraux ()</term><term>Antiviraux (pharmacologie)</term><term>Antiviraux (synthèse chimique)</term><term>Chimie pharmaceutique ()</term><term>Concentration inhibitrice 50</term><term>Conception de médicament</term><term>Conformation moléculaire</term><term>Cysteine endopeptidases ()</term><term>Domaine catalytique</term><term>Esters</term><term>Humains</term><term>Liaison aux protéines</term><term>Modèles chimiques</term><term>Modèles moléculaires</term><term>Protéines virales (antagonistes et inhibiteurs)</term><term>Virus du SRAS (métabolisme)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Viral Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antiviral Agents</term><term>Cysteine Endopeptidases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines virales</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Chemistry, Pharmaceutical</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Catalytic Domain</term><term>Drug Design</term><term>Esters</term><term>Humans</term><term>Inhibitory Concentration 50</term><term>Models, Chemical</term><term>Models, Molecular</term><term>Molecular Conformation</term><term>Protein Binding</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Animaux</term><term>Antiviraux</term><term>Chimie pharmaceutique</term><term>Concentration inhibitrice 50</term><term>Conception de médicament</term><term>Conformation moléculaire</term><term>Cysteine endopeptidases</term><term>Domaine catalytique</term><term>Esters</term><term>Humains</term><term>Liaison aux protéines</term><term>Modèles chimiques</term><term>Modèles moléculaires</term><term>Synthèse chimique</term><term>Antiviral</term><term>Relation structure activité</term><term>In vitro</term><term>Cysteine endopeptidases</term><term>Virus syndrome respiratoire aigu sévère</term><term>Hétérocycle azote</term><term>Composé bicyclique</term><term>Composé aromatique</term><term>Dérivé de la pyridine</term><term>Modèle moléculaire</term><term>Complexe enzyme inhibiteur</term><term>Modélisation</term><term>Inhibiteur enzyme</term><term>Indole-4-carboxylique acide ester 5-chloro-3-pyridyle</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Design, synthesis and biological evaluation of a series of 5-chloropyridine ester-derived severe acute respiratory syndrome-coronavirus chymotrypsin-like protease inhibitors is described. Position of the carboxylate functionality is critical to potency. Inhibitor 10 with a 5-chloropyridinyl ester at position 4 of the indole ring is the most potent inhibitor with a SARS-CoV 3CLpro IC<sub>50</sub> value of 30 nM and an antiviral EC<sub>50</sub> value of 6.9 μM. Molecular docking studies have provided possible binding modes of these inhibitors.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Illinois</li><li>Indiana</li></region><settlement><li>Chicago</li></settlement><orgName><li>Université de Chicago</li><li>Université de l'Illinois à Chicago</li></orgName></list><tree><country name="États-Unis"><region name="Indiana"><name sortKey="Ghosh, Arun K" sort="Ghosh, Arun K" uniqKey="Ghosh A" first="Arun K." last="Ghosh">Arun K. Ghosh</name></region><name sortKey="Baker, Susan C" sort="Baker, Susan C" uniqKey="Baker S" first="Susan C." last="Baker">Susan C. Baker</name><name sortKey="Coughlin, Melissa" sort="Coughlin, Melissa" uniqKey="Coughlin M" first="Melissa" last="Coughlin">Melissa Coughlin</name><name sortKey="Gangli Gong" sort="Gangli Gong" uniqKey="Gangli Gong" last="Gangli Gong">GANGLI GONG</name><name sortKey="Grum Tokars, Valerie" sort="Grum Tokars, Valerie" uniqKey="Grum Tokars V" first="Valerie" last="Grum-Tokars">Valerie Grum-Tokars</name><name sortKey="Johnson, Michael E" sort="Johnson, Michael E" uniqKey="Johnson M" first="Michael E." last="Johnson">Michael E. Johnson</name><name sortKey="Mesecar, Andrew D" sort="Mesecar, Andrew D" uniqKey="Mesecar A" first="Andrew D." last="Mesecar">Andrew D. Mesecar</name><name sortKey="Mulhearn, Debbie C" sort="Mulhearn, Debbie C" uniqKey="Mulhearn D" first="Debbie C." last="Mulhearn">Debbie C. Mulhearn</name><name sortKey="Prabhakar, Bellur S" sort="Prabhakar, Bellur S" uniqKey="Prabhakar B" first="Bellur S." last="Prabhakar">Bellur S. Prabhakar</name><name sortKey="Sleeman, Katrina" sort="Sleeman, Katrina" uniqKey="Sleeman K" first="Katrina" last="Sleeman">Katrina Sleeman</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003511 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003511 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:09-0033367
|texte= Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors
}}
| This area was generated with Dilib version V0.6.33. |  |